Fig. 5From: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case seriesOverall and Progression Free survival. (a) 12-month overall survival. (b) 12-month progression free survival. Data expressed as time since T-VEC injection (n = 10). Dotted line represents ± standard of errorBack to article page